Business
Pfizer is going further than Covid. Why its stock is a buy.
Pfizer has probably done more than any other company to help normalize the world from the pandemic, and it has reaped a huge financial hit from its twin Covid-19 franchise — the vaccine. Best seller and top treatment, Paxlovid.
However, the world has stopped worrying about Covid—and Pfizer (ticker: PFE) is paying the price. The sales of the two Covid blockbusters could drop by more than 60% in 2023, after generating a combined $57 billion in 2022. And there is considerable demand uncertainty for both films. this in the coming years.